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CORRESPONDENCE
Re. ‘Provision of Vascular Surgery in England in 2012’
Grewal et al.1 rightly claim the importance of assessing the
state of vascular surgery in England at this time of signiﬁ-
cant change and development of specialty status. However,
there are some potentially serious inaccuracies. In the
‘Results’ section the authors say 167 out of 169 Trusts
(98.8%) replied, but go on to say that four Trusts did not
reply. This appears to be inconsistent.
They also state that only 80 of the 167 Trusts who
responded to the Freedom of Information (FOI) requests
provide vascular surgery services. Furthermore, the two
ﬁgures in the article appear to have red ﬂags, presumably
representing the hub (Figure 1) and non-hub (Figure 2)
vascular providers. Although the text records 48 hub hos-
pitals and 32 non-hub hospitals, the ﬁgures seem to
represent different numbers of each, although Norfolk and
Cornwall are not included in the ﬁgures.
The text does not provide a list of Trusts in each category,
but some sites are named in the ﬁgures, but are indicated
as neither hub nor non-hub hospitals.When the FOI request
responses for Durham and Darlington NHS Trust, Mid
Yorkshire Hospitals NHS Trust (Wakeﬁeld), Chesterﬁeld and
Derby were reviewed they all said they provide vascular
services yet are not clearly represented in the article.
The authors may wish to carefully review the source of
their data, available at whatdotheyknow.com because there
is a risk that they have misrepresented the responses,
making their conclusions about the provision of vascular
surgery inaccurate.
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Re. ‘Re. Provision of Vascular Surgery in England in 2012’
We welcome the comments by Mr Curley regarding our
paper on provision of vascular surgery in England in 2012.1
There is a typographical error and it should indeed state
that only two trusts did not reply.The questionnaire represents a snapshot of vascular
services in relation to early 2012. The situation may have
changed by now. The aim of the paper was to assess in
the most objective way and directly from the Trusts how
the centralisation process was developing. The maps
were intended as a visual representation of the more
detailed tables, especially for readers unfamiliar with
English cities.
Addressing the speciﬁc trusts mentioned, the data is
available in the tables provided within the paper. Royal
Derby Hospitals NHS Foundation Trust and County Durham
and Darlington NHS Foundation Trust are documented in
Table 1 as hub hospitals. Within the West Yorkshire Central
County, Mid Yorkshire Hospitals NHS Trust is documented as
centralising with Leeds Teaching Hospitals NHS Trust, but
continuing to provide arterial surgery at the Mid Yorkshire
site. Chesterﬁeld have stated that they are looking to
centralise with Derby and as such were not mentioned
separately.
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Re. ‘Cost-effectiveness of Vascular Access for
Haemodialyis: Arteriovenous Fistulas Versus
Arteriovenous Grafts’
We read with interest the paper of Leermakers et al.1 We
propose that rather than comparing the cost-effectiveness
of arteriovenous ﬁstulas (AVF) and arteriovenous grafts
(AVG) the real question is: What is the most cost-effective
way to provide safe renal replacement therapy (RRT) to
patients with end-stage renal disease (ESRD)?
Infection is undoubtedly one of the greatest threats to
patient well-being while receiving RRT, and poses a signiﬁ-
cant cost to healthcare providers.
